Relay Therapeutics, Inc. Operating Expenses
Relay Therapeutics, Inc. (RLAY) reported Operating Expenses of $91.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Relay Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $91.17M, a 17.61% increase year-over-year.
- Relay Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $81.59M, a 11.84% decline year-over-year.
- Relay Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $67.63M, a 20.42% decline year-over-year.
- Relay Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $80.39M, a 16.58% decline year-over-year.
- Relay Therapeutics, Inc. operating expenses for fiscal 2025 was $318.09M, a 16.83% decline from fiscal 2024.
- Relay Therapeutics, Inc. operating expenses for fiscal 2024 was $382.48M, a 4.03% decline from fiscal 2023.
- Relay Therapeutics, Inc. operating expenses for fiscal 2023 was $398.55M, a 32.56% increase from fiscal 2022.
- Relay Therapeutics, Inc. operating expenses for fiscal 2022 was $300.66M, a 18.24% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $91.17M 10-Q · filed 2026-08-06 | $172.76M 10-Q · filed 2026-08-06 | $240.39M derived: sum of 3 quarters · filed 2026-08-06 | $320.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $81.59M 10-Q · filed 2026-05-05 | $149.22M derived: sum of 2 quarters · filed 2026-05-05 | $229.61M derived: sum of 3 quarters · filed 2026-05-05 | $307.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $67.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $148.02M derived: sum of 2 quarters · filed 2026-02-26 | $225.54M derived: sum of 3 quarters · filed 2026-08-06 | $318.09M 10-K · filed 2026-02-26 |
| 2025-09-30 | $80.39M 10-Q · filed 2025-11-06 | $157.91M derived: sum of 2 quarters · filed 2026-08-06 | $250.46M 10-Q · filed 2025-11-06 | $335.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $77.52M 10-Q · filed 2026-08-06 | $170.07M 10-Q · filed 2026-08-06 | $255.05M derived: sum of 3 quarters · filed 2026-08-06 | $351.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $92.55M 10-Q · filed 2026-05-05 | $177.53M derived: sum of 2 quarters · filed 2026-05-05 | $273.90M derived: sum of 3 quarters · filed 2026-05-05 | $374.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $84.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $181.35M derived: sum of 2 quarters · filed 2026-02-26 | $282.11M derived: sum of 3 quarters · filed 2026-02-26 | $382.48M 10-K · filed 2026-02-26 |
| 2024-09-30 | $96.37M 10-Q · filed 2025-11-06 | $197.13M derived: sum of 2 quarters · filed 2025-11-06 | $297.50M 10-Q · filed 2025-11-06 | $389.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $100.76M 10-Q · filed 2025-08-07 | $201.13M 10-Q · filed 2025-08-07 | $293.32M derived: sum of 3 quarters · filed 2026-02-26 | $392.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $100.37M 10-Q · filed 2025-05-05 | $192.56M derived: sum of 2 quarters · filed 2026-02-26 | $291.34M derived: sum of 3 quarters · filed 2026-02-26 | $397.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $92.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $190.97M derived: sum of 2 quarters · filed 2026-02-26 | $297.14M derived: sum of 3 quarters · filed 2026-02-26 | $398.55M 10-K · filed 2026-02-26 |
| 2023-09-30 | $98.78M 10-Q · filed 2024-11-06 | $204.95M derived: sum of 2 quarters · filed 2024-11-06 | $306.35M 10-Q · filed 2024-11-06 | $379.45M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $106.17M 10-Q · filed 2024-08-06 | $207.57M 10-Q · filed 2024-08-06 | $280.68M derived: sum of 3 quarters · filed 2025-02-26 | $366.91M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $101.40M 10-Q · filed 2024-05-02 | $174.51M derived: sum of 2 quarters · filed 2025-02-26 | $260.74M derived: sum of 3 quarters · filed 2025-02-26 | $338.92M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $73.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $159.34M derived: sum of 2 quarters · filed 2025-02-26 | $237.52M derived: sum of 3 quarters · filed 2025-02-26 | $300.66M 10-K · filed 2025-02-26 |
| 2022-09-30 | $86.24M 10-Q · filed 2023-11-02 | $164.41M derived: sum of 2 quarters · filed 2023-11-02 | $227.55M 10-Q · filed 2023-11-02 | $295.84M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $78.18M 10-Q · filed 2023-08-08 | $141.32M 10-Q · filed 2023-08-08 | $209.61M derived: sum of 3 quarters · filed 2024-02-22 | $271.26M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $63.14M 10-Q · filed 2023-05-04 | $131.43M derived: sum of 2 quarters · filed 2024-02-22 | $193.09M derived: sum of 3 quarters · filed 2024-02-22 | $387.51M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $68.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $129.95M derived: sum of 2 quarters · filed 2024-02-22 | $324.37M derived: sum of 3 quarters · filed 2024-02-22 | $367.73M 10-K · filed 2024-02-22 |
| 2021-09-30 | $61.66M 10-Q · filed 2022-11-03 | $256.08M derived: sum of 2 quarters · filed 2022-11-03 | $299.44M 10-Q · filed 2022-11-03 | $347.10M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $194.42M 10-Q · filed 2022-08-04 | $237.78M 10-Q · filed 2022-08-04 | $285.45M derived: sum of 3 quarters · filed 2023-02-23 | $322.05M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $43.36M 10-Q · filed 2022-05-05 | $91.02M derived: sum of 2 quarters · filed 2023-02-23 | $127.63M derived: sum of 3 quarters · filed 2023-02-23 | $155.35M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $47.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $84.27M derived: sum of 2 quarters · filed 2023-02-23 | $111.99M derived: sum of 3 quarters · filed 2023-02-23 | $138.45M 10-K · filed 2023-02-23 |
| 2020-09-30 | $36.61M 10-Q · filed 2021-11-10 | $64.33M derived: sum of 2 quarters · filed 2021-11-10 | $90.78M 10-Q · filed 2021-11-10 | $116.62M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $27.72M 10-Q · filed 2021-08-12 | $54.18M 10-Q · filed 2021-08-12 | $80.01M derived: sum of 3 quarters · filed 2022-02-24 | $101.92M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $26.46M 10-Q · filed 2021-05-13 | $52.29M derived: sum of 2 quarters · filed 2022-02-24 | $74.20M derived: sum of 3 quarters · filed 2022-02-24 | $94.10M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $25.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $47.74M derived: sum of 2 quarters · filed 2022-02-24 | $67.65M derived: sum of 3 quarters · filed 2022-02-24 | $84.05M 10-K · filed 2022-02-24 |
| 2019-09-30 | $21.91M 10-Q · filed 2020-11-12 | $41.81M derived: sum of 2 quarters · filed 2020-11-12 | $58.22M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $19.91M 10-Q · filed 2020-08-27 | $36.31M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |